Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction

Launched by CLINICAL HOSPITAL CENTRE ZAGREB · Mar 23, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how certain genetic factors can affect the way people respond to cardiovascular medications, particularly in predicting adverse reactions or side effects from these drugs. Researchers want to understand how genetic differences in individuals might influence the risks associated with medications like blood thinners (NOACs), antiplatelet drugs (like clopidogrel), and cholesterol-lowering statins. Over the next 4.5 years, the trial aims to recruit around 1,200 adults who will be starting these medications, and they will carefully analyze any side effects experienced by participants.

To be eligible for this study, participants need to be at least 18 years old and must be prescribed one of the medications mentioned for at least three months. They will also need to give their consent to participate and provide blood samples for genetic testing. Throughout the trial, participants can expect to undergo regular evaluations and have their health monitored closely. Importantly, all personal information will be kept private and secure. The goal of the study is to identify specific genetic markers that could help predict which patients are more likely to experience side effects from these cardiovascular drugs, potentially leading to better, personalized treatment approaches in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • a) age 18 years or older; b) a new indication for the administration of any of the medicinal products of primary interest (NOAC, clopidogrel, prasugrel, ticagrelor, statins) for which at least a 3-month administration is predicted; c) signed informed consent (for repeated evaluations and donation of blood samples for genetic and eventual pharmacokinetic analysis).
• Exclusion Criteria:
• • the existence of contraindications to the medicines of primary interest.